U.S. Markets close in 3 hrs
  • S&P 500

    4,155.40
    -30.07 (-0.72%)
     
  • Dow 30

    34,007.66
    -193.01 (-0.56%)
     
  • Nasdaq

    13,866.13
    -186.21 (-1.33%)
     
  • Russell 2000

    2,221.15
    -41.52 (-1.83%)
     
  • Crude Oil

    63.28
    +0.15 (+0.24%)
     
  • Gold

    1,771.60
    -8.60 (-0.48%)
     
  • Silver

    25.77
    -0.33 (-1.26%)
     
  • EUR/USD

    1.2042
    +0.0062 (+0.5178%)
     
  • 10-Yr Bond

    1.5910
    +0.0180 (+1.14%)
     
  • Vix

    18.45
    +2.20 (+13.54%)
     
  • GBP/USD

    1.3988
    +0.0148 (+1.0687%)
     
  • USD/JPY

    108.0570
    -0.7260 (-0.6674%)
     
  • BTC-USD

    54,853.93
    -626.31 (-1.13%)
     
  • CMC Crypto 200

    1,233.83
    -65.13 (-5.01%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Recap: Vericel Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Vericel (NASDAQ:VCEL) rose 1.0% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 25.00% year over year to $0.25, which beat the estimate of $0.20.

Revenue of $45,229,000 up by 14.82% year over year, which beat the estimate of $45,000,000.

Outlook

The upcoming fiscal year's revenue expected to be between $161,000,000 and $164,000,000.

Conference Call Details

Date: Feb 24, 2021

View more earnings on VCEL

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/zxxjppat

Price Action

52-week high: $53.98

52-week low: $6.78

Price action over last quarter: Up 112.90%

Company Overview

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and the goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. The Company operates in one reportable segment: the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.